Target intelligence / Profile preview

Extracellular matrix protein 1 (ECM1)

Target
ECM1
Molecular classification
Other (Secreted extracellular matrix glycoprotein)
01

Overview

Extracellular matrix protein 1 (ECM1) is a secreted glycoprotein found in the extracellular matrix of most tissues and exists in multiple isoforms arising from alternative splicing (notably ECM1a, ECM1b, ECM1c, and ECM1d). ECM1 plays an essential role in structural support, modulation of cell growth and differentiation, angiogenesis, and maintenance of skin integrity, and it interacts with a variety of structural extracellular proteins. Mutations in ECM1 lead to lipoid proteinosis, a rare genetic disorder characterized by skin and mucosal abnormalities, while overexpression—particularly of the ECM1a isoform—promotes tumorigenesis and therapy resistance in multiple types of cancer, partly through integrin binding and activation of downstream AKT/FAK signaling pathways. ECM1 is a focus of emerging research in oncology for its value as a potential biomarker and as a target for anti-cancer therapy, though direct targeting agents are not yet in clinical use.

Other names
Secretory component p85URBWDTesticular tissue protein Li 61ECM1aECM1bECM1cECM1d
02

Mechanism of action

Not applicable; specific drugs targeting ECM1 are not currently established

03

Biological functions

Extracellular matrix organizationRegulation of cell growth and differentiationAngiogenesis (blood vessel formation)Cell signalingTumorigenesis and cancer progressionMaintenance of skin integrity and homeostasis
04

Disease associations

Cancer (including ovarian, breast, gastric, esophageal, and hepatocellular carcinoma)Lipoid proteinosis (Urbach-Wiethe disease)Skin and mucosal disorders
05

Safety considerations

Disease associations with loss-of-function (lipoid proteinosis) or overexpression (cancer)Chronic targeting could disrupt normal extracellular matrix and skin homeostasis, causing skin/mucosal abnormalities
06

Interacting drugs

None currently FDA-approved or widely recognized; no small-molecule or biologic drugs are established to directly target ECM1 as of now
07

Biomarkers

ECM1 expression as a prognostic marker in several cancersMutations in ECM1 gene as diagnostic or confirmatory for lipoid proteinosis

Beyond the preview

Go deeper on Extracellular matrix protein 1 (ECM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extracellular matrix protein 1 (ECM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call